{"id":"W2267533929","doi":"10.1200/jco.2015.33.15_suppl.4508","title":"Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sunitinib; Rash; Renal cell carcinoma; Sorafenib; Adverse effect; Discontinuation; Placebo; Internal medicine; Clinical endpoint; Toxicity; Urology; Adjuvant; Neutropenia; Surgery; Randomized controlled trial; Hepatocellular carcinoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001731378,0.0007390368,0.001080674,0.0004095637,0.0002263774,0.0005962686,0.0006581356,0.000717027,0.004728681],"category_scores_gemma":[0.001105787,0.0003255671,0.001182729,0.0004129673,0.0004888943,0.0004493855,0.0003484489,0.001614558,0.0005152664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009104155,"about_ca_system_score_gemma":0.001061319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009480074,"about_ca_topic_score_gemma":0.00313251,"domain_scores_codex":[0.9994094,0.0003821348,0.00002820426,0.00006318867,0.00005634656,0.00006067588],"domain_scores_gemma":[0.9994879,0.0001102856,0.0001405995,0.00004763305,0.00002979035,0.0001838444],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9292499,0.009265164,0.005109829,0.0004063271,0.0009877252,0.00007989287,0.00007830853,0.002275964,0.007276649,0.0002911039,0.001959643,0.04301954],"study_design_scores_gemma":[0.7653349,0.2087958,0.01658225,0.00003646717,0.0008995978,0.0002941642,0.00003053794,0.002826823,0.002079434,0.0003875291,0.0027072,0.00002530868],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940233,0.001299528,0.0006735381,0.0002373429,0.00004276251,0.0008023819,0.0008190987,0.00009653255,0.002005503],"genre_scores_gemma":[0.9935359,0.00061426,0.001244218,0.0003474,0.00006918635,0.0009610251,0.001533653,0.00002005039,0.001674369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004728681,"threshold_uncertainty_score":0.01581901,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3894171637368761,"score_gpt":0.5368922467804587,"score_spread":0.1474750830435826,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}